Endometrial stromal sarcomas (ESS) are a rare group of malignant mesenchymal tumors arising from the connective tissue of the endometrium, which resemble cells in their proliferative stage. These tumors represent 6-20% of uterine sarcomas and less than 1% of primary uterine malignancies; being low-grade, the most frequently diagnosed. Diagnosis is based on surgical pathology, but imaging plays a very important role in staging, considering that approximately 30-50% of patients have extra uterine spread at the time of diagnosis, and this determines treatment. MRI can determine with high accuracy the extension and invasion of the lesion, but 18F-FDG PET/CT is more accurate for the detection of abnormal lymph nodes and distant metastases, thus combining these two modalities is the best approach.
No takes yet. Share an insight, caveat, or question.
Murad et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: